» Articles » PMID: 31915285

Human Epitopes Identified from Herpes Simplex Virus Tegument Protein VP11/12 (UL46) Recall Multifunctional Effector Memory CD4 T Cells in Asymptomatic Individuals and Protect from Ocular Herpes Infection and Disease in "Humanized" HLA-DR Transgenic...

Abstract

While the role of CD8 T cells in the control of herpes simplex virus 1 (HSV-1) infection and disease is gaining wider acceptance, a direct involvement of effector CD4 T cells in this protection and the phenotype and function of HSV-specific human CD4 T cell epitopes remain to be fully elucidated. In the present study, we report that several epitopes from the HSV-1 virion tegument protein (VP11/12) encoded by UL46 are targeted by CD4 T cells from HSV-seropositive asymptomatic individuals (who, despite being infected, never develop any recurrent herpetic disease). Among these, we identified two immunodominant effector memory CD4 T cell epitopes, amino acids (aa) 129 to 143 of VP11/12 (VP11/12) and VP11/12, using , , and approaches based on the following: (i) a combination of the TEPITOPE algorithm and PepScan library scanning of the entire 718 aa of HSV-1 VP11/12 sequence; (ii) an peptide-protein docking analysis and binding assay that identify epitopes with high affinity to soluble HLA-DRB1 molecules; and (iii) an ELISpot assay and intracellular detection of gamma interferon (IFN-γ), CD107 degranulation, and CD4 T cell carboxyfluorescein succinimidyl ester (CFSE) proliferation assays. We demonstrated that native VP11/12 and VP11/12 epitopes presented by HSV-1-infected HLA-DR-positive target cells were recognized mainly by effector memory CD4 T cells while being less targeted by FOXP3 CD4 CD25 regulatory T cells. Furthermore, immunization of HLA-DR transgenic mice with a mixture of the two immunodominant human VP11/12 CD4 T cell epitopes, but not with cryptic epitopes, induced HSV-specific polyfunctional IFN-γ-producing CD107 CD4 T cells associated with protective immunity against ocular herpes infection and disease. We report that naturally protected HSV-1-seropositive asymptomatic individuals develop a higher frequency of antiviral effector memory CD4 T cells specific to two immunodominant epitopes derived from the HSV-1 tegument protein VP11/12. Immunization of HLA-DR transgenic mice with a mixture of these two immunodominant CD4 T cell epitopes induced a robust antiviral CD4 T cell response in the cornea that was associated with protective immunity against ocular herpes. The emerging concept of developing an asymptomatic herpes vaccine that would boost effector memory CD4 and CD8 T cell responses is discussed.

Citing Articles

An updated review of HSV-1 infection-associated diseases and treatment, vaccine development, and vector therapy application.

Su D, Han L, Shi C, Li Y, Qian S, Feng Z Virulence. 2024; 15(1):2425744.

PMID: 39508503 PMC: 11562918. DOI: 10.1080/21505594.2024.2425744.


Immunological Considerations for the Development of an Effective Herpes Vaccine.

Singer M, Husseiny M Microorganisms. 2024; 12(9).

PMID: 39338520 PMC: 11434158. DOI: 10.3390/microorganisms12091846.


Herpes simplex keratitis: A brief clinical overview.

Musa M, Enaholo E, Aluyi-Osa G, Atuanya G, Spadea L, Salati C World J Virol. 2024; 13(1):89934.

PMID: 38616855 PMC: 11008405. DOI: 10.5501/wjv.v13.i1.89934.


Flagellin-Fused Protein Targeting M2e and HA2 Induces Innate and T-Cell Responses in Mice of Different Genetic Lines.

Stepanova L, Shuklina M, Vasiliev K, Kovaleva A, Vidyaeva I, Zabrodskaya Y Vaccines (Basel). 2022; 10(12).

PMID: 36560509 PMC: 9786633. DOI: 10.3390/vaccines10122098.


Influenza B: Prospects for the Development of Cross-Protective Vaccines.

Tsybalova L, Stepanova L, Ramsay E, Vasin A Viruses. 2022; 14(6).

PMID: 35746794 PMC: 9228933. DOI: 10.3390/v14061323.


References
1.
. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease Study Group. N Engl J Med. 1998; 339(5):300-6. DOI: 10.1056/NEJM199807303390503. View

2.
Dervillez X, Qureshi H, Chentoufi A, Khan A, Kritzer E, Yu D . Asymptomatic HLA-A*02:01-restricted epitopes from herpes simplex virus glycoprotein B preferentially recall polyfunctional CD8+ T cells from seropositive asymptomatic individuals and protect HLA transgenic mice against ocular herpes. J Immunol. 2013; 191(10):5124-38. PMC: 4057607. DOI: 10.4049/jimmunol.1301415. View

3.
Kalantari-Dehaghi M, Chun S, Chentoufi A, Pablo J, Liang L, Dasgupta G . Discovery of potential diagnostic and vaccine antigens in herpes simplex virus 1 and 2 by proteome-wide antibody profiling. J Virol. 2012; 86(8):4328-39. PMC: 3318641. DOI: 10.1128/JVI.05194-11. View

4.
Srivastava R, Roy S, Coulon P, Vahed H, Prakash S, Dhanushkodi N . Therapeutic Mucosal Vaccination of Herpes Simplex Virus 2-Infected Guinea Pigs with Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Local Tissue-Resident CD4 and CD8 T Cells Associated with Protection against.... J Virol. 2019; 93(9). PMC: 6475797. DOI: 10.1128/JVI.02309-18. View

5.
Reul J, Frisch J, Engeland C, Thalheimer F, Hartmann J, Ungerechts G . Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors. Front Oncol. 2019; 9:52. PMC: 6382738. DOI: 10.3389/fonc.2019.00052. View